next-seq platform Search Results


illumina nextseq 500 550 platform  (Illumina Inc)
99
Illumina Inc illumina nextseq 500 550 platform
Illumina Nextseq 500 550 Platform, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/illumina nextseq 500 550 platform/product/Illumina Inc
Average 99 stars, based on 1 article reviews
illumina nextseq 500 550 platform - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
next seq platform  (Illumina Inc)
98
Illumina Inc next seq platform
Next Seq Platform, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/next seq platform/product/Illumina Inc
Average 98 stars, based on 1 article reviews
next seq platform - by Bioz Stars, 2026-03
98/100 stars
  Buy from Supplier
sequencing platforms nextseq  (NextGen Sciences)
90
NextGen Sciences sequencing platforms nextseq
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
Sequencing Platforms Nextseq, supplied by NextGen Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sequencing platforms nextseq/product/NextGen Sciences
Average 90 stars, based on 1 article reviews
sequencing platforms nextseq - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
whole genome sequencing using illumina nextseq platform  (Illumina Inc)
90
Illumina Inc whole genome sequencing using illumina nextseq platform
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
Whole Genome Sequencing Using Illumina Nextseq Platform, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/whole genome sequencing using illumina nextseq platform/product/Illumina Inc
Average 90 stars, based on 1 article reviews
whole genome sequencing using illumina nextseq platform - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nextseq or novaseq 6000 platforms  (Illumina Inc)
90
Illumina Inc nextseq or novaseq 6000 platforms
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
Nextseq Or Novaseq 6000 Platforms, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nextseq or novaseq 6000 platforms/product/Illumina Inc
Average 90 stars, based on 1 article reviews
nextseq or novaseq 6000 platforms - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
n500 blocking oligo primers  (Illumina Inc)
90
Illumina Inc n500 blocking oligo primers
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
N500 Blocking Oligo Primers, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/n500 blocking oligo primers/product/Illumina Inc
Average 90 stars, based on 1 article reviews
n500 blocking oligo primers - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
genomic dna isolated from formalin fixed paraffin embedded (ffpe) tumor samples using the illumina nextseq platform  (Illumina Inc)
90
Illumina Inc genomic dna isolated from formalin fixed paraffin embedded (ffpe) tumor samples using the illumina nextseq platform
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
Genomic Dna Isolated From Formalin Fixed Paraffin Embedded (Ffpe) Tumor Samples Using The Illumina Nextseq Platform, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/genomic dna isolated from formalin fixed paraffin embedded (ffpe) tumor samples using the illumina nextseq platform/product/Illumina Inc
Average 90 stars, based on 1 article reviews
genomic dna isolated from formalin fixed paraffin embedded (ffpe) tumor samples using the illumina nextseq platform - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nextseq platform using nextera xt library preparation kit  (Illumina Inc)
90
Illumina Inc nextseq platform using nextera xt library preparation kit
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
Nextseq Platform Using Nextera Xt Library Preparation Kit, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nextseq platform using nextera xt library preparation kit/product/Illumina Inc
Average 90 stars, based on 1 article reviews
nextseq platform using nextera xt library preparation kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
qiaseq mirna sequencing platform nextseq 500  (Qiagen)
90
Qiagen qiaseq mirna sequencing platform nextseq 500
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
Qiaseq Mirna Sequencing Platform Nextseq 500, supplied by Qiagen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/qiaseq mirna sequencing platform nextseq 500/product/Qiagen
Average 90 stars, based on 1 article reviews
qiaseq mirna sequencing platform nextseq 500 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
150 × 2 illumina nextseq 500 platform  (Illumina Inc)
90
Illumina Inc 150 × 2 illumina nextseq 500 platform
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
150 × 2 Illumina Nextseq 500 Platform, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/150 × 2 illumina nextseq 500 platform/product/Illumina Inc
Average 90 stars, based on 1 article reviews
150 × 2 illumina nextseq 500 platform - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nextseq sequencer platform  (Illumina Inc)
90
Illumina Inc nextseq sequencer platform
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
Nextseq Sequencer Platform, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nextseq sequencer platform/product/Illumina Inc
Average 90 stars, based on 1 article reviews
nextseq sequencer platform - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nextseq 1000 platform  (Illumina Inc)
90
Illumina Inc nextseq 1000 platform
Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA <t>sequencing.</t> Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.
Nextseq 1000 Platform, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nextseq 1000 platform/product/Illumina Inc
Average 90 stars, based on 1 article reviews
nextseq 1000 platform - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA sequencing. Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma

doi: 10.1158/1078-0432.CCR-21-3581

Figure Lengend Snippet: Molecular alterations seen in KRAS-WT tumors. 1A: Mutation rates detected by NGS. 1B: Alteration rates detected by immunohistochemistry, copy number amplification rates detected by NGS and fusion rates detected by RNA sequencing. Bars are color coded according to the oncogenic pathways of each biomarker. 1C: BRAF mutations seen in the cohort categorized into class 1, 2 and 3 based on mechanism of action.

Article Snippet: Treatment and survival information were available from a total of 5324 pancreatic cancer patients tested as either KRAS WT (N=705) or KRAS MT (N=4619) using NextGen sequencing platforms (NextSeq or Novaseq).

Techniques: Mutagenesis, Immunohistochemistry, Amplification, RNA Sequencing, Biomarker Discovery

Volcano plot comparing molecular alterations of KRAS MT vs. WT tumors. NGS: Next-Gen Sequencing detected mutations. Only molecular alterations significantly different (adjusted p<0.05) are labeled. Full results can be found in Supplemental table 4.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma

doi: 10.1158/1078-0432.CCR-21-3581

Figure Lengend Snippet: Volcano plot comparing molecular alterations of KRAS MT vs. WT tumors. NGS: Next-Gen Sequencing detected mutations. Only molecular alterations significantly different (adjusted p<0.05) are labeled. Full results can be found in Supplemental table 4.

Article Snippet: Treatment and survival information were available from a total of 5324 pancreatic cancer patients tested as either KRAS WT (N=705) or KRAS MT (N=4619) using NextGen sequencing platforms (NextSeq or Novaseq).

Techniques: Sequencing, Labeling

An oncoprint displaying the molecular alteration patten of the 233 PDAC tumors. Each row represents a biomarker of either fusion, mutation or copy number amplification, as well as genomic signatures such as TMB or MSI/MMR. Red, blue and green represents TMB-H, MSI-high/MMR-deficient or mutations detected using DNA-sequencing; green represents copy number amplification detected by DNA sequencing, while navy blue represents fusions detected by RNA Sequencing. Grey represents no alteration detected while blanks represent unavailable data (indeterminate results due to low coverage or noisy signals). Bars on the right represents the prevalence of molecular alterations of each row.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma

doi: 10.1158/1078-0432.CCR-21-3581

Figure Lengend Snippet: An oncoprint displaying the molecular alteration patten of the 233 PDAC tumors. Each row represents a biomarker of either fusion, mutation or copy number amplification, as well as genomic signatures such as TMB or MSI/MMR. Red, blue and green represents TMB-H, MSI-high/MMR-deficient or mutations detected using DNA-sequencing; green represents copy number amplification detected by DNA sequencing, while navy blue represents fusions detected by RNA Sequencing. Grey represents no alteration detected while blanks represent unavailable data (indeterminate results due to low coverage or noisy signals). Bars on the right represents the prevalence of molecular alterations of each row.

Article Snippet: Treatment and survival information were available from a total of 5324 pancreatic cancer patients tested as either KRAS WT (N=705) or KRAS MT (N=4619) using NextGen sequencing platforms (NextSeq or Novaseq).

Techniques: Biomarker Discovery, Mutagenesis, Amplification, DNA Sequencing, RNA Sequencing

Comparison of Tumor Microenvironment (TME) characteristics in KRAS MT vs. WT tumors. 5A: Lymphocyte cell fractions estimated by RNA sequencing using Quantiseq.5B: Stromal cell populations estimated by RNA sequencing using MCP counter.**: significantly different after correcting for multiple comparison; * trending differences.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Molecular characterization of KRAS wild type tumors in patients with pancreatic adenocarcinoma

doi: 10.1158/1078-0432.CCR-21-3581

Figure Lengend Snippet: Comparison of Tumor Microenvironment (TME) characteristics in KRAS MT vs. WT tumors. 5A: Lymphocyte cell fractions estimated by RNA sequencing using Quantiseq.5B: Stromal cell populations estimated by RNA sequencing using MCP counter.**: significantly different after correcting for multiple comparison; * trending differences.

Article Snippet: Treatment and survival information were available from a total of 5324 pancreatic cancer patients tested as either KRAS WT (N=705) or KRAS MT (N=4619) using NextGen sequencing platforms (NextSeq or Novaseq).

Techniques: Comparison, RNA Sequencing